BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Analyst Earnings Estimates
NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 641.01% | N/A 400.69% | N/A 113.59% | N/A 87.58% | N/A 68.32% | N/A 10.13% | ||||||||
| EBITDA YoY % growth | -4.1M | -8.86M -116.10% | -29.28M -230.47% | -69.52M -137.43% | -126.66M -82.19% | -92.32M 27.11% | -86.023M 6.82% | N/A 6.86% | N/A 13.83% | N/A -13.62% | N/A -13.02% | N/A 22.37% | N/A 201.32% | N/A 316.79% | N/A 82.01% | N/A 40.57% | |
| EBIT YoY % growth | -4.12M | -8.9M -116.02% | -29.33M -229.55% | -69.57M -137.20% | -126.87M -82.36% | -92.83M 26.83% | -86.46M 6.86% | N/A 6.73% | N/A -6.62% | N/A -37.95% | N/A -22.82% | N/A 27.14% | N/A 122.81% | N/A 786.04% | N/A 196.26% | N/A 1.10% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.05 69.63% | -3.47 -69.22% | -2.52 27.36% | -1.88 25.40% | N/A 29.47% | N/A 5.92% | N/A -23.60% | N/A -2.80% | N/A 46.20% | N/A 174.16% | N/A 298.79% | N/A 113.14% | N/A 2.37% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 5.59% | -0.30 14.56% | -0.31 14.48% | -0.33 -16.21% | -0.34 -6.76% | -0.22 24.96% | -0.23 23.80% | -0.17 46.71% | -0.17 49.40% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -18.36M 10.08% | -16.687M 17.23% | -16.789M 23.54% | -17.442M 2.41% | -18.136M 1.22% | -19.38M -16.14% | -19.349M -15.25% | -19.829M -13.68% | -20.349M -12.20% |
| EBIT Q2Q % growth | -18.857M 9.58% | -19.287M 4.74% | -21.133M 4.50% | -22.965M -26.67% | -25.132M -33.27% | -18.972M 1.63% | -19.421M 8.10% | -19.89M 13.39% | -20.41M 18.79% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.28 37.78% | -0.38 | 0.10 | 26.57% |
| Q2 2024 Q2Q % growth | -0.36 30.77% | -0.39 | 0.03 | 8.83% |
| Q1 2024 Q2Q % growth | -0.35 38.60% | -0.44 | 0.09 | 21.12% |
| Q4 2023 Q2Q % growth | -0.34 42.37% | -0.48 | 0.14 | 28.47% |
| Q3 2023 Q2Q % growth | -0.45 25.00% | -0.50 | 0.05 | 9.32% |
| Q2 2023 Q2Q % growth | -0.52 17.46% | -0.55 | 0.03 | 4.86% |
| Q1 2023 Q2Q % growth | -0.57 18.57% | -0.62 | 0.05 | 8.01% |
| Q4 2022 Q2Q % growth | -0.59 16.90% | -0.64 | 0.05 | 7.84% |
| Q3 2022 Q2Q % growth | -0.60 38.14% | -0.65 | 0.05 | 8.09% |
| Q2 2022 Q2Q % growth | -0.63 33.68% | -0.69 | 0.06 | 9.20% |
| Q1 2022 Q2Q % growth | -0.70 16.57% | -0.77 | 0.07 | 8.66% |
| Q4 2021 Q2Q % growth | -0.71 -12.70% | -1.03 | 0.32 | 31.31% |
| Q3 2021 Q2Q % growth | -0.97 -94.00% | -1.00 | 0.03 | 2.80% |
| Q2 2021 Q2Q % growth | -0.95 -131.71% | -0.86 | -0.09 | -10.83% |
| Q1 2021 Q2Q % growth | -0.84 -64.51% | -0.69 | -0.15 | -21.29% |
| Q4 2020 Q2Q % growth | -0.63 86.39% | -0.64 | 0.01 | 1.96% |
| Q3 2020 Q2Q % growth | -0.50 | -0.53 | 0.03 | 6.45% |
| Q2 2020 Q2Q % growth | -0.41 | -0.45 | 0.04 | 9.47% |
| Q1 2020 Q2Q % growth | -0.51 | -0.49 | -0.02 | -3.31% |
| Q4 2019 Q2Q % growth | -4.63 | -1.40 | -3.23 | -231.33% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 14.17% | 0% | 7.85% |
| Revenue | N/A | N/A | N/A | N/A |